US equities |
MU $913.92 ▼-0.02% NVDA $217.32 ▼-1.80% SNDK $1,364.70 ▼-2.75% SPCX $148.80 ▼-2.21% AMD $549.85 ▼-3.67% INTC $94.41 ▼-3.78% TSM $420.18 ▼-2.28% AAPL $343.06 ▲+0.03%
FinancialContent

argenx SE - American Depositary Shares (NQ:ARGX)

851.09 +32.79 (+4.01%)
Delayed Quote Updated: 11:20 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
From argenx SE
Via GlobeNewswire
News headline image
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Thursday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
From argenx SE
Via GlobeNewswire
ARGENX SE - ADR (NASDAQ:ARGX) Meets Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
News headline image
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
From argenx SE
Via GlobeNewswire
News headline image
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? ↗
This biotech stock could soar 30% or more over the next 12 months if some analysts are right. 
Via The Motley Fool
News headline image
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
From argenx SE
Via GlobeNewswire
News headline image
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months ↗
There are good reasons behind analyst's bullish views of this biotech stock. 
Via The Motley Fool
News headline image
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. ↗
It's easy to be bullish about Argenx. 
Via The Motley Fool
News headline image
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
From argenx SE
Via GlobeNewswire
News headline image
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of... 
Via Benzinga
News headline image
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
This biotech innovator could be in only the early chapters of its success story. 
Via The Motley Fool
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
argenx Completes Acquisition of Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story ↗
This biotech leader continues to rack up clinical successes. 
Via The Motley Fool
News headline image
Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC... 
Via Benzinga
News headline image
These Analysts Boost Their Forecasts On Argenx ↗
Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock. 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing ↗
argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients... 
Via MarketBeat
Topics Intellectual Property
News headline image
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of... 
Via Benzinga
News headline image
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From argenx SE
Via GlobeNewswire
News headline image
Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of... 
Via Benzinga
News headline image
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
From argenx SE
Via GlobeNewswire
News headline image
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102 ↗
argenex (NASDAQ:ARGX) said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for... 
Via MarketBeat
Topics Intellectual Property
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
From Forte Biosciences, Inc.
Via Business Wire
News headline image
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
From argenx SE
Via GlobeNewswire
News headline image
argenex Q2 Earnings Call Highlights ↗
argenex (NASDAQ:ARGX) reported what executives described as one of its strongest quarters to date, driven by continued growth for VYVGART across myasthenia gravis and chronic inflammatory demyelinating... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >